Person › Details
Benoît Adelus (Sebia S.A.)
Adelus, Benoît (Sebia 200802– before Eurofins EVP + bioMérieux CEO + Merial)
|Product||capillary electrophoresis (CE)|
|Product 2||diagnostics (medical/biological)|
PerkinElmer, Inc.. (5/23/14). "Press Release: PerkinElmer to Serve as Exclusive Global Distributor for Sebia’s Hemoglobin Newborn Screening System".
Expands Extensive Neonatal Testing Menu to Include Fully Automated Hemoglobin Platform for Immediate Detection and Diagnosis of Inherited Genetic Conditions
WHAT: PerkinElmer Inc., a global leader focused on the health and safety of people and the environment, today announced an agreement to become the exclusive global distributor for Sebia's CAPILLARYS™ 2 NEONAT FAST offering to newborn screening laboratories. This system enables fully automated hemoglobin newborn screening from dried blood spot samples by capillary electrophoresis.
This year, more than 10 million babies will be screened at birth for several hemoglobinopathies (inherited genetic conditions affecting the number or shape of red blood cells), including sickle cell disease. Detecting these types of conditions through newborn screening can better enable immediate delivery of vaccinations and treatments with antibiotics to prevent infections.
"As a global leader in newborn screening for more than 25 years, we continue to expand our innovative panel of testing options, particularly as we are finding that our customers are evolving from manual to automated approaches," said Prahlad Singh, President, Diagnostics, PerkinElmer. "Sebia's offering complements our hemoglobin screening portfolio by providing laboratories with an automated option, which can help them obtain clinically actionable information and insights to achieve better outcomes."
"We are pleased to collaborate with PerkinElmer and leverage its global footprint and market leadership in newborn screening to provide greater access to our hemoglobin screening capabilities -- helping laboratory professionals to detect life threatening diseases," said Benoit Adelus, CEO and Chairman for Sebia.
HOW IT WORKS: Sebia's hemoglobin newborn screening assay is designed to separate normal hemoglobins and detect hemoglobin variants. The CAPILLARYS 2 NEONAT FAST capillary electrophoresis system provides high resolution separation and complete walk-away automation from hemolysate preparation to final color-coded results. For more information, please visit http://www.sebia-usa.com/products/capillarys2nnf.html
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.2 billion in 2013, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Sebia, a world leader in protein electrophoresis, analysis, develops, manufactures and markets, assays and analyzers, dedicated to the clinical diagnosis of multiple myeloma, inflammatory diseases, diabetes, alcohol dependence and hemoglobin disorders. Sebia products are sold in more than 110 countries, for a sales turnover of 153 M€ in 2013. www.sebia.com.
Record changed: 2016-03-20
More documents for Benoît Adelus
-  PerkinElmer, Inc.. (5/23/14). "Press Release: PerkinElmer to Serve as Exclusive Global Distributor for Sebia’s Hemoglobin Newborn Screening System"....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to email@example.com and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]